Skip to main content
. 2023 Aug 21;129(8):1274–1283. doi: 10.1038/s41416-023-02403-x

Fig. 1. Identification of study population.

Fig. 1

HER2 human epidermal growth factor receptor-2, NAHT neoadjuvant anti-HER2 therapy, pCR pathological complete response.